Triolein emulsion enhances temozolomide brain delivery: an experimental study in rats.
Animals
Antineoplastic Agents, Alkylating
/ administration & dosage
Blood-Brain Barrier
/ metabolism
Brain
/ metabolism
Chemistry, Pharmaceutical
Dose-Response Relationship, Drug
Drug Delivery Systems
/ methods
Emulsions
/ chemistry
Male
Rats
Rats, Sprague-Dawley
Temozolomide
/ administration & dosage
Triolein
/ chemistry
BBB
Triolein emulsion
drug delivery
liquid chromatography
temozolomide
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
4
2
2022
Statut:
ppublish
Résumé
To evaluate the enhancement of temozolomide (TMZ) delivery in the rat brain using a triolein emulsion. Rats were divided into the five groups as following: group 1 (negative control), group 2 (treated with triolein emulsion and TMZ 20 mg/kg), and group 3 (TMZ 20 mg/kg treatment without triolein), group 4 (treated with triolein emulsion and TMZ 10 mg/kg), and group 5 (TMZ 10 mg/kg treatment without triolein). Triolein emulsion was infused into the right common carotid artery. One hour later, the TMZ concentration was evaluated quantitatively and qualitatively using high-performance liquid chromatography (HPLC-MS) and desorption electrospray ionization mass spectrometry (DESI-MS) imaging, respectively. The concentration ratios of the ipsilateral to contralateral hemisphere in each group were determined and the statistical analysis was conducted using an unpaired Quantitatively, the TMZ concentration ratio of the ipsilateral to the control hemisphere was 2.41 and 1.13 in groups 2 and 3, and were 2.49 and 1.14 in groups 4 and 5, respectively. Thus, the TMZ signal intensities of TMZ in group 2 and 4 were statistically high in the ipsilateral hemispheres. Qualitatively, the signal intensity of TMZ was remarkably high in the ipsilateral hemisphere in group 2 and 4. The triolein emulsion efficiently opened the blood-brain barrier and could provide a potential new strategy to enhance the therapeutic effect of TMZ. HPLC-MS and DESI-MS imaging were shown to be suitable for analyses of enhancement of brain TMZ concentrations.
Identifiants
pubmed: 34747271
doi: 10.1080/10717544.2021.1998247
pmc: PMC8583762
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Emulsions
0
Triolein
122-32-7
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2373-2382Références
J Med Chem. 1984 Feb;27(2):196-201
pubmed: 6694168
Invest Radiol. 2004 Jul;39(7):445-9
pubmed: 15194916
Pharmacol Res. 2007 Oct;56(4):275-87
pubmed: 17897837
Expert Rev Neurother. 2010 Oct;10(10):1537-44
pubmed: 20925470
Cancer Chemother Pharmacol. 2010 Mar;65(4):727-34
pubmed: 19641919
Microscopy (Oxf). 2017 Oct 1;66(5):366-370
pubmed: 29016922
Neurosurgery. 2016 May;78(5):726-33
pubmed: 26540353
Invest Radiol. 2001 Aug;36(8):460-9
pubmed: 11500597
Anal Chem. 2015 Mar 17;87(6):3286-93
pubmed: 25710577
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11121-6
pubmed: 24982150
J Neurooncol. 2006 Mar;77(1):89-94
pubmed: 16292488
Acta Pol Pharm. 2012 Nov-Dec;69(6):1347-55
pubmed: 23285701
J Neurooncol. 2003 Feb;61(3):203-7
pubmed: 12675312
World J Gastroenterol. 2021 Jan 14;27(2):152-161
pubmed: 33510556
AJNR Am J Neuroradiol. 2006 Feb;27(2):398-401
pubmed: 16484418
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Br J Cancer. 1999 Nov;81(6):1022-30
pubmed: 10576660
Curr Med Chem. 2009;16(2):245-57
pubmed: 19149575
Drug Discov Today. 2007 Jan;12(1-2):54-61
pubmed: 17198973
Xenobiotica. 2004 May;34(5):487-500
pubmed: 15370964
J Cell Mol Med. 2013 Oct;17(10):1218-35
pubmed: 23998913
AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):958-63
pubmed: 15205130
J Signal Transduct. 2012;2012:735135
pubmed: 22685651
Biochim Biophys Acta. 2011 Nov;1811(11):946-60
pubmed: 21645635
Biochemistry. 1994 Aug 9;33(31):9045-51
pubmed: 8049205
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
pubmed: 15173079
J Inherit Metab Dis. 2013 May;36(3):437-49
pubmed: 23609350
Acta Radiol. 2010 Jun;51(5):563-8
pubmed: 20350246
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15184-9
pubmed: 25246570
Analyst. 2015 Feb 21;140(4):1090-8
pubmed: 25521825
Br J Cancer. 1998 Sep;78(5):652-61
pubmed: 9744506
Acta Vet Scand. 2009 Jul 16;51:30
pubmed: 19604410
Angew Chem Int Ed Engl. 2005 Nov 4;44(43):7094-7
pubmed: 16259018
Ophthalmic Res. 2009;41(1):14-20
pubmed: 18849637
PLoS One. 2014 Dec 09;9(12):e114311
pubmed: 25490097
J Pharm Biomed Anal. 2001 Jan;24(3):461-8
pubmed: 11199225
Science. 2004 Oct 15;306(5695):471-3
pubmed: 15486296
Science. 2006 Mar 17;311(5767):1566-70
pubmed: 16543450
Cancer Res. 1984 May;44(5):1772-5
pubmed: 6713381
Curr Pharm Biotechnol. 2012 Sep;13(12):2380-7
pubmed: 23016643
Mol Cancer. 2011 Oct 11;10:128
pubmed: 21988793
Oncologist. 2000;5(2):144-51
pubmed: 10794805
PLoS One. 2013 Apr 29;8(4):e61512
pubmed: 23637844
Acta Radiol. 2008 Dec;49(10):1174-81
pubmed: 19031181
J Neurooncol. 2016 Feb;126(3):433-9
pubmed: 26626489
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42
pubmed: 19430790
Neurosurgery. 2011 Feb;68(2):280-89; discussion 290
pubmed: 21135749